• Deferoxamine Mesylate: Precision Iron-Chelating Agent Workfl

  2026-06-05

  Deferoxamine mesylate is redefining experimental models of iron metabolism, oxidative stress, and hypoxia. This article delivers actionable protocols, advanced use-cases, and troubleshooting insights to help researchers harness this iron-chelating agent for next-generation cancer and tissue protection assays.

• Inducing Embryonic Dormancy In Vitro via mTOR Inhibition Pro

  2026-06-05

  The study by Iyer et al. presents a robust, noninvasive protocol for inducing a reversible, diapause-like dormant state in mammalian early embryonic cells through pharmacological inhibition of mTOR. This approach offers new avenues for dissecting the molecular underpinnings of embryonic dormancy and expands the potential for high-throughput and translational research in reproductive biology.

• Cationic Lipids Modulate Immunogenicity in mRNA-LNP Vaccines

  2026-06-04

  This study systematically examines how cationic lipid incorporation into mRNA lipid nanoparticles (LNPs) modulates immunogenicity and vaccine efficacy. The findings reveal that precise adjustment of cationic lipid composition allows fine-tuning of innate immune activation and antitumor responses, offering practical guidance for optimizing mRNA vaccine design.

• AI-Driven Discovery of Senolytics: Implications for EGFR/Erb

  2026-06-04

  The reference study demonstrates a machine learning approach to identifying novel senolytic compounds, validating three candidates in human senescent cell models. This innovation dramatically reduces drug screening costs and highlights new avenues for therapeutic targeting of senescence-linked diseases.

• MLKL Polymerization Drives Necroptosis via Lysosomal Catheps

  2026-06-03

  The reference study uncovers how MLKL polymerization at lysosomal membranes induces membrane permeabilization, triggering the release of cathepsin B and promoting necroptosis. These insights clarify the temporal and mechanistic relationship between lysosomal rupture and cell death, offering precise intervention targets for researchers studying regulated necrosis and inflammation.

• Bestatin Hydrochloride in Angiogenesis and Tumor Research

  2026-06-03

  Bestatin hydrochloride (Ubenimex) empowers researchers to dissect angiogenesis inhibition and tumor invasion with precision. This guide details stepwise workflows, experimental enhancements, and troubleshooting strategies—translating literature-backed findings into reproducible, data-rich assays.

• Optimized Extraction and Bioactivity of O. raphanipies Polys

  2026-06-02

  This study details the ultrasonic-assisted extraction (UAE) of Oudemansiella raphanipies polysaccharides (ORP), optimizing yield and characterizing their structural and functional properties. The findings reveal high antioxidant and prebiotic potential, with implications for food and biomedical research.

• DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid): Rel

  2026-06-02

  This article addresses critical workflow challenges in cell viability, proliferation, and cytotoxicity assays, showing how DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid) (SKU B7675) delivers reproducible, data-backed solutions. Drawing on peer-reviewed evidence and practical scenarios, it guides researchers toward improved assay reliability and mechanistic insight.

• Verapamil HCl: Mechanistic Leverage for Translational Resear

  2026-06-01

  Explore how Verapamil HCl, an L-type calcium channel blocker, transcends its cardiovascular origins to empower next-generation oncology and inflammation research. This article synthesizes mechanistic insights, experimental best practices, and strategic guidance for translational investigators, highlighting Verapamil HCl’s role in modulating apoptosis, overcoming drug resistance, and attenuating inflammation—while offering a competitive perspective on protocol design and future directions.

• 5-(N,N-dimethyl)-Amiloride Hydrochloride in Endothelial Rese

  2026-06-01

  5-(N,N-dimethyl)-Amiloride hydrochloride empowers researchers to dissect Na+/H+ exchanger signaling in models of endothelial injury, cardiac dysfunction, and pH regulation. Explore stepwise protocols, advanced use-cases, and troubleshooting strategies that leverage APExBIO’s high-purity C3505 for reproducible, translational insights.

• Bufalin Targets STK33: Mechanistic Advances in TNBC Research

  2026-05-31

  A recent study identifies Serine/Threonine Kinase 33 (STK33) as a new, direct molecular target of Bufalin in triple-negative breast cancer (TNBC). This mechanistic insight reveals Bufalin’s ability to degrade STK33, suppressing TNBC progression and highlighting a promising therapeutic avenue.

• G007-LK: Potent Tankyrase 1/2 Inhibitor for Wnt/β-catenin Re

  2026-05-30

  G007-LK is a highly selective tankyrase 1/2 inhibitor enabling precise modulation of the Wnt/β-catenin signaling pathway and β-catenin degradation in APC-mutant cancer models. Benchmarked in both cell-based and in vivo studies, G007-LK demonstrates nanomolar efficacy and robust antitumor activity.

• Zosuquidar (LY335979) 3HCl: Molecular Precision in P-gp-Medi

  2026-05-29

  Discover how Zosuquidar (LY335979) 3HCl drives molecularly precise inhibition of P-glycoprotein, redefining strategies for overcoming multidrug resistance in cancer. This article offers advanced mechanistic insights and practical assay guidance beyond the standard workflow focus.

• Tyrothricin Peptide Antibiotic: Workflow Mastery & Antimicro

  2026-05-29

  Tyrothricin, a potent peptide antibiotic mixture from APExBIO, bridges fundamental membrane disruption mechanisms with reliable, cross-kingdom infection control. This article empowers researchers with protocol refinements, troubleshooting expertise, and actionable insights drawn from the latest studies and expert workflows.

• CPI-613: Unlocking Cuproptosis and Epigenetic Vulnerabilitie

  2026-05-28

  Discover how CPI-613, a novel mitochondrial metabolism inhibitor, enables advanced apoptosis assays and tumor cell metabolism studies by targeting cuproptosis and epigenetic reprogramming. This article uniquely explores CPI-613’s implications for overcoming drug resistance in cancer research.

16368 records 1/1092 page Next 12345 下5页 Last page